Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugs for Hearing Loss: A Sound Opportunity

This article was originally published in Start Up

Executive Summary

Hearing loss is an arena largely ignored by the biopharmaceutical industry, with most of the innovation coming from med-tech players. That situation is ripe for change as a vanguard of start-ups is attempting to develop novel therapies to treat a variety of hearing disorders, including Ménière's disease and sudden sensorineural hearing loss.

You may also be interested in...



Otonomy Sustained-Release Gels May Solve Ear Med Delivery Problems

Otonomy has moved two candidates into registration trials for middle and inner ear disorders and plans to have a third ready for the clinic next year.

New GSK Spin-Out Targets Hearing Loss

The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.

New GSK Spin-Out Targets Hearing Loss

The second spin-out to emerge after GSK's 2010 exit from neurosciences-related R&D, Autifony Therapeutics may receive up to 10 million pounds in Series A funding to develop preclinical assets for hearing disorders.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel